DGAP-Adhoc: M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG
DGAP-Ad-hoc: M1 Kliniken AG / Key word(s): Investment/Investment
M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG
15-Dec-2020 / 15:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
M1 Kliniken AG disposes subsidiary "M1 Aesthetics GmbH" to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG
Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company's share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.01.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.
M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with an enterprise value of a good € 58 million. The new HAEMATO shares were issued at a reference price of €23.55 per share, which corresponds to the volume-weighted average price of HAEMATO AG in the Xetra trading system in the period from 27.11.2020 to 9.12.2020.
In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - also due to corona effects, among other things. A further increase in earnings is expected in the coming years.
About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia.
Contact:
M1 Kliniken AG
Dr. Walter von Horstig, Management Board
Grünauer Straße 5
12557 Berlin
Telefon: +49 (0)30 347 47 44 14
E-Mail: [email protected]
15-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
M1 Kliniken AG |
|
Grünauer Straße 5 |
|
12557 Berlin |
|
Germany |
Phone: |
+49 (0)30 347 47 44 14 |
Fax: |
+49 (0)30 347 47 44 17 |
E-mail: |
[email protected] |
Internet: |
https://www.m1-kliniken.de |
ISIN: |
DE000A0STSQ8 |
WKN: |
A0STSQ |
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1155296 |
|
End of Announcement |
DGAP News Service |
1155296 15-Dec-2020 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
47,19 |
65,21 |
77,27 |
159,59 |
314,61 |
285,29 |
302,00 |
EBITDA1,2 |
6,18 |
7,17 |
11,33 |
8,89 |
17,82 |
15,41 |
19,85 |
EBITDA-Marge3 |
13,10 |
11,00 |
14,66 |
5,57 |
5,66 |
5,40 |
|
EBIT1,4 |
5,71 |
6,46 |
7,93 |
4,41 |
12,13 |
9,35 |
14,40 |
EBIT-Marge5 |
12,10 |
9,91 |
10,26 |
2,76 |
3,86 |
3,28 |
4,77 |
Jahresüberschuss1 |
5,78 |
6,61 |
9,73 |
7,43 |
10,88 |
7,07 |
9,50 |
Netto-Marge6 |
12,25 |
10,14 |
12,59 |
4,66 |
3,46 |
2,48 |
3,15 |
Cashflow1,7 |
2,09 |
2,86 |
-5,37 |
9,54 |
15,68 |
20,77 |
0,00 |
Ergebnis je Aktie8 |
0,38 |
0,39 |
0,56 |
0,37 |
0,45 |
0,22 |
0,39 |
Dividende8 |
0,30 |
0,30 |
0,00 |
0,00 |
0,00 |
0,00 |
0,30 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: wetreu NTRG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
M1 Kliniken |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0STSQ |
13,850 |
Kaufen |
272,06 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
20,07 |
28,20 |
0,72 |
36,54 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,78 |
13,10 |
0,95 |
16,93 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
17.07.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
06.06.2024 |
03.09.2024 |
16.11.2023 |
23.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
9,56% |
37,72% |
23,66% |
97,29% |
|
|